Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun 25;15(13):3333.
doi: 10.3390/cancers15133333.

HER-2-Positive Tumors: A Continuously Evolving Field in Cancer Research

Ralf Hofheinz  1 , Sylvie Lorenzen  2 , Michael K Bohlmann  3
Affiliations
Editorial

HER-2-Positive Tumors: A Continuously Evolving Field in Cancer Research

Ralf Hofheinz et al. Cancers (Basel). .

Abstract

Almost 25 years ago, trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), was licensed for the treatment of patients with metastatic HER2-positive breast cancer in the United States of America (USA) [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. doi: 10.1016/S0140-6736(10)61121-X. - DOI - PubMed
    1. Tabernero J., Hoff P.M., Shen L., Ohtsu A., A Shah M., Cheng K., Song C., Wu H., Eng-Wong J., Kim K., et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19:1372–1384. doi: 10.1016/S1470-2045(18)30481-9. - DOI - PubMed
    1. Thuss-Patience P.C., A Shah M., Ohtsu A., Van Cutsem E., A Ajani J., Castro H., Mansoor W., Chung H.C., Bodoky G., Shitara K., et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18:640–653. doi: 10.1016/S1470-2045(17)30111-0. - DOI - PubMed
    1. Hecht J.R., Bang Y.J., Qin S.K., Chung H.C., Xu J.M., Park J.O., Jeziorski K., Shparyk Y., Hoff P.M., Sobrero A., et al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial. J. Clin. Oncol. 2016;34:443–451. doi: 10.1200/JCO.2015.62.6598. - DOI - PubMed
    1. Shitara K., Bang Y.-J., Iwasa S., Sugimoto N., Ryu M.-H., Sakai D., Chung H.-C., Kawakami H., Yabusaki H., Lee J., et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N. Engl. J. Med. 2020;382:2419–2430. doi: 10.1056/NEJMoa2004413. - DOI - PubMed

Publication types